Back to search

From the notice

W911SR-25-S-GUIDE Notice Type: Special Announcement Synopsis: This is a solicitation for parties interested in participating in projects sought by the The Joint Project Lead Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies (JPL-CBRND-EB) (JPL EB). JPL EB has the mission to accelerate the delivery of medical countermeasures to the warfighter through the development and implementation of platform systems. Generative Unconstrained Intelligence Drug Engineering (GUIDE) is an integrated computational and experimental platform designed to accelerate medical countermeasure development. GUIDE harnesses the power of advanced simulation and machine learning to enable preparedness and facilitate rapid response to protect the warfighter from a diverse and dynamic threat space. GUIDE impacts the discovery and design of biological products (e.g., monoclonal antibodies and vaccines) as well as small molecule drugs by simultaneously optimizing critical quality attributes of safety, efficacy, manufacturability and pharmacokinetics/pharmacodynamics while concurrently accounting for critical design attributes affecting developability and biophysical properties. GUIDE is a collaboration between U.S. interagency, academic and industry partners and is closely linked to the Accelerated Antibodies, Rapid Access to Products in Development (RAPID), Vaccine Acceleration by Modular Progression (VAMP), and Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.